奥泰生物收盘下跌1.93%，滚动市盈率17.26倍，总市值52.40亿元

Core Viewpoint - The company, Aotai Biological Technology Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the context of its strong revenue and profit growth [1][2]. Company Summary - Aotai Biological specializes in the research, production, and sales of in vitro diagnostic reagents, with a diverse product range exceeding 1,200 types, including rapid diagnostic reagents for drug abuse detection, infectious disease testing, women's health, tumor detection, and cardiac markers [1]. - The company has received multiple accolades, including being recognized as one of the top 500 innovative high-tech enterprises in Zhejiang Province and one of the top 50 medical device companies in China for 2022-2023 [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 618 million yuan, representing a year-on-year increase of 10.37%, and a net profit of 198 million yuan, reflecting a significant year-on-year growth of 94.48% [2]. - The company's gross profit margin stands at 55.76%, indicating strong profitability [2]. Market Position - As of the latest report, Aotai Biological's rolling PE ratio is 17.26, significantly lower than the industry average of 45.94 and the median of 29.64, positioning the company at 38th in the industry ranking [1][2]. - The total market capitalization of Aotai Biological is 5.24 billion yuan, with 158 institutions holding a total of 8.18 million shares valued at 517 million yuan [1].